English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912721      Online Users : 1191
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12468


    Title: Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
    Authors: Yen, FS;Yang, YC;Hwu, CM;Wei, JC;Huang, YH;Hou, MC;Hsu, CC
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND & AIMS: Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short-term with moderate sample size, no liver-related long-term outcomes could be noted. METHODS: This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality between TZD users and nonusers. The Kaplan-Meier method was used to compare the cumulative incidence of these main outcomes. RESULTS: The incidence rates of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality during follow-up were 0.77 versus 1.95, 1.43 versus 1.75, 0.36 versus 0.70, and 4.89 versus 3.78 per 1000 person-years between TZD users and nonusers. The adjusted hazard ratios of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality were 0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 (95% CI: 0.18-1.17), and 1.18 (95% CI: 0.87-1.61), respectively. CONCLUSIONS: Our study demonstrated that TZD use could significantly lower the risk of liver cirrhosis. In clinical settings, TZD use might be able to improve liver-related long-term outcomes.
    Date: 2020-05
    Relation: Liver International. 2020 May;40(5):1089-1097.
    Link to: http://dx.doi.org/10.1111/liv.14385
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000512129200001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079445831
    Appears in Collections:[許志成] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB31960563.pdf12920KbAdobe PDF320View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback